Navamedic ASA: Launch of new products strengthen the category of Medical Nutrition
Oslo June 1th, 2021 – Navamedic ASA (“Navamedic”, OSE: NAVA) announces the launch of new products in the Nordics.
Medical Nutrition is a strategically important area for Navamedic and to further strengthen our presence, we have now launched three new products in this category. The first to be launched is Glycosade Lemon for the dietary treatment of Glycogen Storage Disease (GSD), an inborn error of metabolism. The other two, K.Flo and K.Yo, are both used for the dietary management of drug-resistant epilepsy or other conditions for which a ketogenic diet is indicated.
“We are proud to announce that the addition of these new products to the existing portfolio will enhance our strategy of delivering a complete range of products for patients with metabolic disorders or drug-resistant epilepsy. This will give patients who are on a very strict dietary regimens an increased choice of options which will make the adherence to dietary treatment easier.” says Fredrik Karlsson, KAM Medical Nutrition of Navamedic.
Navamedic has products that combine the best of cutting-edge research with the lifestyle demands of modern living. By launching new products to meet complex dietary treatments, Navamedic will continue to offer new product lines throughout the year, always with the patient at the core.
The Medical Nutrition business segment is based on the sale of products for the treatment of inborn errors of metabolism (IEM). Within Medical Nutrition, Navamedic is a Nordic distributor of products purchased from the UK based company Vitaflo International ltd, a subsidiary of Nestlé. Navamedic’s vendor Vitaflo has more than 30 years of experience in producing specialist nutritional products for Inborn Errors of Metabolism (IEM).
For more information, please contact:
Alexander Lidmejer, Commercial Director Specialty Pharma at Navamedic ASA, +46 70 257 99 71 alexander.lidmejer@navamedic.com
About Navamedic
Navamedic ASA is a Nordic pharma company and reliable provider of high-quality products, delivered to hospitals and through pharmacies, meeting the specific needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com